Publication: Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis
Issued Date
2017-05-01
Resource Type
ISSN
19326203
Other identifier(s)
2-s2.0-85019745364
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE. Vol.12, No.5 (2017)
Suggested Citation
Darwin J. Operario, Alexander F. Koeppel, Stephen D. Turner, Yongde Bao, Suporn Pholwat, Sayera Banu, Suporn Foongladda, Stellah Mpagama, Jean Gratz, Oleg Ogarkov, Svetlana Zhadova, Scott K. Heysell, Eric R. Houpt Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis. PLoS ONE. Vol.12, No.5 (2017). doi:10.1371/journal.pone.0176522 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/41450
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis
Abstract
© 2017 Operario et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Amplicon-based Next Generation Sequencing (NGS) is an emerging method for Mycobacterium tuberculosis drug susceptibility testing (DST) but has not been well described. We examined 158 clinical multidrug-resistant M. tuberculosis isolates via NGS of 11 resistance-associated gene regions covering 3519 nucleotides. Across these gene regions, complete resistance or heteroresistance (defined as 1%-99% mutation) was present in at least one isolate in 6.3% of loci. The number of isolates with heteroresistance was highest for gyrA codon 94, rpoB codons 526 and 531, and embB codons 306, 372 and 406 (range 11-26% of isolates exhibited heteroresistance). 57% of MDR strains had heteroresistance of one or more recognized resistance-associated mutation. Heteroresistant loci generally exhibited high or low degrees of mutation (>90% or <10%). The deep sensitivity of NGS for detecting low level pncA heteroresistance appeared to improve genotypic-phenotypic PZA susceptibility correlations over that of Sanger. NGS demonstrates that heteroresistance in TB in the regions of key genes is common and will need to be bioinformatically managed. The clinical significance of such heteroresistance is unclear, and further study of pncA should be pursued.